Drug Adverse Reaction Target Database (DART)

An adverse drug reaction (ADR) often results from interaction of a drug or its metabolites with specific protein targets important in normal cellular function. Knowledge about these targets is both important in facilitating the study of the mechanisms of ADRs and in new drug discovery. It is also useful in the development and testing of rational drug design and safety evaluation tools. The Drug Adverse Reaction Database (DART) is intended to provide comprehensive information about adverse effect targets of drugs described in the literature. Moreover, proteins involved in adverse effect targets of chemicals not yet confirmed as ADR targets are also included as potential targets. This database gives physiological function of each target, binding drugs/agonists/antagonists/activators/inhibitors, IC50 values of the inhibitors, corresponding adverse effects, and type of ADR induced by drug binding to a target. Cross-links to other databases are also introduced to facilitate the access of information about the sequence, 3-dimensional structure, function, and nomenclature of each target along with drug/ligand binding properties, and related literature. The database currently contains entries for 147 ADR targets and 89 potential targets. A total of 187 adverse reaction conditions, 257 drugs, and 1080 ligands known to bind to each of these targets are also currently described. Each entry can be retrieved through multiple search methods including target name, target physiological function, adverse effect, ligand name, and biological pathways. A special page is provided for contribution of new or additional information. This database can be accessed at http://xin.cz3.nus.edu.sg/group/drt/dart.asp.

[1]  Curtis D. Klaassen,et al.  Casarett and Doull's Toxicology. The Basic Science of Poisons , 1981 .

[2]  D. R. Robinson.  Prostaglandins and the mechanism of action of anti-inflammatory drugs. , 1983, The American journal of medicine.

[3]  R. Howell,et al.  Mechanism for the emetic side effect of xanthine bronchodilators. , 1990, Life sciences.

[4]  E. Gillam,et al.  Immunotoxic Side-Effects of Drug Therapy , 1990, Drug safety.

[5]  E. Beutler.  Galactosemia: screening and diagnosis. , 1991, Clinical biochemistry.

[6]  Y. C. Liu,et al.  Glutathione peroxidase and catalase modulate the genotoxicity of arsenite. , 1997, Toxicology.

[7]  Pumford Nr,et al.  Protein targets of xenobiotic reactive intermediates. , 1997 .

[8]  Sense and non-sense in toxicity assessment of medicinal products , 1997 .

[9]  C. Alderman.  Perhexiline-Paroxetine Drug Interaction , 1998 .

[10]  A. Sali.  100,000 protein structures for the biologist , 1998, Nature Structural Biology.

[11]  T. Monks,et al.  The pharmacology and toxicology of polyphenolic-glutathione conjugates. , 1998, Annual review of pharmacology and toxicology.

[12]  M D Barratt,et al.  Integrating computer prediction systems with in vitro methods towards a better understanding of toxicology. , 1998, Toxicology letters.

[13]  Michael Y. Galperin,et al.  Beyond complete genomes: from sequence to structure and function. , 1998, Current opinion in structural biology.

[14]  A. Bairoch,et al.  The SWISS-PROT protein sequence data bank and its supplement TrEMBL in 1999 , 1999, Nucleic Acids Res..

[15]  Alan Dove,et al.  Proteomics: translating genomics into products? , 1999, Nature Biotechnology.

[16]  D. Gerhold,et al.  DNA chips: promising toys have become powerful tools. , 1999, Trends in biochemical sciences.

[17]  J. Trent,et al.  Microarrays and toxicology: The advent of toxicogenomics , 1999, Molecular carcinogenesis.

[18]  M Pirmohamed,et al.  Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. , 2000, Toxicology.

[19]  Nenad Blau,et al.  The neurochemistry of phenylketonuria , 2000, European Journal of Pediatrics.

[20]  E. Vesell,et al.  Advances in Pharmacogenetics and Pharmacogenomics , 2000, Journal of clinical pharmacology.

[21]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[22]  A. Starkov,et al.  Mitochondrial targets of drug toxicity. , 2000, Annual review of pharmacology and toxicology.

[23]  M Pirmohamed,et al.  Genetic susceptibility to adverse drug reactions. , 2001, Trends in pharmacological sciences.

[24]  Y. Z. Chen,et al.  Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. , 2001, Journal of molecular graphics & modelling.

[25]  L. L. Smith,et al.  Key challenges for toxicologists in the 21st century. , 2001, Trends in pharmacological sciences.

[26]  S Scharpé,et al.  Peptide truncation by dipeptidyl peptidase IV: a new pathway for drug discovery? , 2001, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie.

[27]  Leena Peltonen,et al.  Dissecting Human Disease in the Postgenomic Era , 2001, Science.

[28]  J McEntyre,et al.  PubMed: bridging the information gap. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[29]  W. Lei,et al.  Pharmacodynamics and Toxicodynamics of Drug Action: Signaling in Cell Survival and Cell Death , 1999, Pharmaceutical Research.